Dyne Therapeutics (NASDAQ:DYN) Price Target Cut to $36.00 by Analysts at Stifel Nicolaus

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) had its price target dropped by equities researchers at Stifel Nicolaus from $66.00 to $36.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Stifel Nicolaus' target price suggests a potential upside of 261.45% from the company's current price.

A number of other equities research analysts have also weighed in on the company. Sanford C. Bernstein assumed coverage on Dyne Therapeutics in a research note on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price target on the stock. Guggenheim reissued a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Jones Trading began coverage on Dyne Therapeutics in a research note on Thursday, June 26th. They issued a "buy" rating and a $30.00 price objective for the company. JPMorgan Chase & Co. dropped their target price on Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a report on Tuesday, July 15th. Finally, Raymond James Financial reiterated an "outperform" rating and set a $31.00 price target (down from $37.00) on shares of Dyne Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $36.25.

Dyne Therapeutics Trading Up 0.5%

DYN stock traded up $0.05 during midday trading on Thursday, reaching $9.96. The company's stock had a trading volume of 1,349,779 shares, compared to its average volume of 2,556,608. The company has a debt-to-equity ratio of 0.17, a quick ratio of 20.35 and a current ratio of 16.83. The stock has a fifty day simple moving average of $10.79 and a two-hundred day simple moving average of $11.55. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $47.45. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -2.56 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.02. On average, equities research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Buying and Selling

In other news, CEO John Cox purchased 100,000 shares of the business's stock in a transaction on Monday, July 14th. The shares were bought at an average price of $9.11 per share, with a total value of $911,000.00. Following the completion of the transaction, the chief executive officer directly owned 242,179 shares in the company, valued at approximately $2,206,250.69. This represents a 70.33% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.14% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. CWM LLC grew its stake in shares of Dyne Therapeutics by 168.1% in the 2nd quarter. CWM LLC now owns 3,030 shares of the company's stock valued at $29,000 after purchasing an additional 1,900 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Dyne Therapeutics by 378.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after buying an additional 2,446 shares in the last quarter. Quarry LP purchased a new stake in shares of Dyne Therapeutics in the first quarter valued at approximately $47,000. GF Fund Management CO. LTD. purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at approximately $50,000. Finally, E Fund Management Co. Ltd. boosted its stake in shares of Dyne Therapeutics by 16.2% in the first quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock valued at $144,000 after buying an additional 1,923 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.